Detalhe da pesquisa
1.
Relationship between Chemotherapy-Induced Diarrhea and Intestinal Microbiome Composition.
Digestion;
104(5): 357-369, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37231829
2.
Therapeutic Drug Monitoring of Golimumab for the Prediction of Long-Term Clinical Remission in Patients with Ulcerative Colitis.
Digestion;
103(5): 329-338, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35697000
3.
Risk Factors for Nephrotoxicity due to Tacrolimus Therapy for Ulcerative Colitis.
Digestion;
103(5): 339-346, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35705006
4.
Comparing the Effects of Anti-TNF Agent and Ustekinumab on Small Bowel Inflammation in Crohn's Disease: Inverse Probability Weighting With Stabilized Weights of Propensity Scores.
Crohns Colitis 360;
6(2): otae033, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38864024
5.
Biomarkers for Monitoring of Changes in Disease Activity in Ulcerative Colitis.
J Clin Med;
12(22)2023 Nov 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38002777
6.
Efficacy of Switching to Adalimumab for Maintenance of Remission Following Induction Therapy with Tacrolimus in Patients with Ulcerative Colitis.
J Clin Med;
12(20)2023 Oct 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37892837
7.
Serum IL-13 Predicts Response to Golimumab in Bio-Naïve Ulcerative Colitis.
J Clin Med;
11(17)2022 Aug 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36078882